enVVeno Medical (NVNOW) Stock Analysis

What enVVeno Medical does

enVVeno Medical Corporation is a medical device firm dedicated to developing advanced bioprosthetic, tissue-based solutions with the aim of elevating the standard of care for various venous diseases. Central to its product pipeline is the VenoValve, a surgical implant currently under development specifically designed to address profound chronic venous insufficiency affecting the deep veins. When surgically positioned within the femoral vein, this innovative device functions as a unidirectional valve, thereby effectively restoring optimal blood flow in the leg. Established in 1999 and headquartered in Irvine, California, the company rebranded as enVVeno Medical Corporation in October 2021, having previously operated under the name Hancock Jaffe Laboratories, Inc.

Key metrics

ETFs linked to NVNOW

Broad-market and Healthcare sector ETFs an investor holding enVVeno Medical is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NVNOW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for enVVeno Medical?

enVVeno Medical trades under the ticker NVNOW on NASDAQ.

Which exchange is NVNOW listed on?

NVNOW is listed on NASDAQ.

What sector does enVVeno Medical operate in?

enVVeno Medical is classified in the Healthcare sector (Medical - Devices industry).

How can PortView help analyze NVNOW in a portfolio?

PortView shows NVNOW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.